Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,832 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- C Clear all
Completed Not applicable Interventional Results available

Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)

NCT01085643
View directory record Official record
Conditions
Constipation-predominant Irritable Bowel Syndrome
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

NCT04175925
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986322, BMS-986322 Placebo, famotidine
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Not applicable Interventional Results available

Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain

NCT02461225
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Erchonia® FX-635™, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 19, 2026, 1:22 PM EDT
Withdrawn Phase 2 Interventional

ACZ885 in Type 1 Diabetes Mellitus

NCT01322321
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Type 1
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of CCX140-B in Subjects With FSGS

NCT03536754
View directory record Official record
Conditions
FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis
Interventions
Placebo, CCX140-B
Other · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Torrance, California • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 19, 2026, 1:22 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments

NCT03704454
View directory record Official record
Conditions
Climacteric; Menorrhagia, Menopausal, Menopause
Interventions
50 mg PYC and then placebo, 100 mg PYC and then placebo, Placebo and then 50 mg PYC, Placebo and then 100 mg PYC
Dietary Supplement
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Gresham, Oregon • Portland, Oregon • Tualatin, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

NCT01950520
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder

NCT00078754
View directory record Official record
Conditions
Intermittent Explosive Disorder
Interventions
Fluoxetine, Divalproex, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Palmar Cooling on the Human Immune System

NCT07215338
View directory record Official record
Conditions
Human Immune Response
Interventions
Muscle Temperature Control
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 19, 2026, 1:22 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes

NCT01265017
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 2 Interventional

Probiotics for Clostridium Difficile Infection in Older Adults

NCT01680874
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes

NCT01681290
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
CBX129801
Drug
Lead sponsor
Cebix Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
22
States / cities
Escondido, California • Fresno, California • Irvine, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2015 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease

NCT04149860
View directory record Official record
Conditions
Healthy, Alzheimer Disease
Interventions
Lu AF87908, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
6
States / cities
Glendale, California • Hollywood, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Pilot Herniorrhaphy Study for Postoperative Analgesia

NCT02504580
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011, Placebo, HTX-002, Bupivacaine HCI (Marcaine), HTX-011A, HTX-011B, HTX-009
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Anaheim, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

NCT01780506
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
78
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 19, 2026, 1:22 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants

NCT07629999
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986533, Famotidine, Placebo, Dabigatran Etexilate, Rosuvastatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 2 Interventional

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

NCT01030432
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-650032, Placebo, Peginterferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • Montgomery, Alabama • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 3 Interventional

Bipolar II Depression: Lithium, SSRI, or the Combination

NCT00276965
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
Sertraline, Lithium carbonate
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 19, 2026, 1:22 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

NCT07000136
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolaemia
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Garden Grove, California • San Diego, California • Miami Lakes, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users

NCT05614544
View directory record Official record
Conditions
General Anesthesia
Interventions
HSK3486, Propofol, Placebo
Drug
Lead sponsor
Haisco-USA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 19, 2026, 1:22 PM EDT
Active, not recruiting Phase 2 Interventional

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06290934
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
emvistegrast, Placebo-to-match emvistegrast
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
57
States / cities
Peoria, Arizona • Camarillo, California • Garden Grove, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

NCT01922921
View directory record Official record
Conditions
HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
HER-2/neu Intracellular Domain Protein, Laboratory Biomarker Analysis, Pertuzumab, Placebo, Polysaccharide-K, Trastuzumab
Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

NCT00697203
View directory record Official record
Conditions
Dyslipidemia
Interventions
Placebo, Pravastatin, Dalcetrapib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
33
States / cities
Mobile, Alabama • Scottsdale, Arizona • Newark, Delaware + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 19, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

NCT01430442
View directory record Official record
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Rimegepant, Placebo, Sumatriptan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 19, 2026, 1:22 PM EDT